Advertisement

Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer

      Highlights

      • Patients treated for differentiated thyroid cancer with different activities.
      • Significant differences in the biokinetics.
      • Correlation between the time-integrated activity and the remnant uptake.

      Abstract

      Purpose

      To study the dependency of the effective half-life on the administered activity and the correlation between the time-integrated activity and the remnant uptake at 2d and 7d in patients treated for DTC with 1.11 GBq, 3.7 GBq or 5.55 GBq of 131I-NaI.

      Methods

      Ninety-two patients undergoing total thyroidectomy and lymph node removal were included. If cancer had not spread to lymph nodes, patients received 1.11 GBq of 131I-NaI when the lesion maximal diameter was smaller than 4 cm, and 3.7 GBq for bigger sizes. If cancer had spread to lymph nodes patients received 5.55 GBq. There were 30, 49 and 13 patients respectively treated with 1.11 GBq(Group 1), 3.7 GBq(Group 2) and 5.55 GBq(Group 3). Two SPECT/CT scans were performed at 2d and 7d after radioiodine administration for each patient to determine the thyroid remnant activities and effective half-lives of the radioiodine.

      Results

      Statistical analysis showed significant differences (p < 0.05) in the effective half-life among patients treated with 1.11 GBq, 3.7 GBq and 5.55 GBq. A high positive correlation (ρ > 0.95) was found between the time-integrated activity and the remnant activity at 2d for the three groups of patients.

      Conclusions

      There were significant differences in the effective half-life of the radioiodine in remnants of patients treated with activities of 1.11 GBq, 3.7 GBq or 5.55 GBq. The high positive linear correlation found between the time-integrated activity and the remnant activity at 2d for the three groups of patients indicate that the time-integrated activity could be estimated from one time-point.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Physica Medica: European Journal of Medical Physics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Silberstein E.B.
        • Alavi A.
        • Balon H.R.
        • Clarke S.E.M.
        • Divgi C.
        • Gelfand M.J.
        • et al.
        The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0.
        J Nucl Med. 2012; 53: 1633-1651
        • Luster M.
        • Clarke S.E.
        • Dietlein M.
        • Lassmann M.
        • Lind P.
        • Oyen W.J.G.
        • et al.
        Guidelines for radioiodine therapy of differentiated thyroid cancer.
        Eur J Nucl Med Mol Imaging. 2008; 35: 1941-1959
        • Clerc J.
        • Verburg F.A.
        • Avram A.M.
        • Giovanella L.
        • Hindié E.
        • Taïeb D.
        Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.
        Eur J Nucl Med Mol Imaging. 2017; 44: 918-925
        • McDougall I.R.
        Management of Thyroid Cancer and Related Nodular Disease.
        Springer-Verlag, London2006
        • Carballo M.
        • Quiros R.M.
        To treat or not to treat: The role of adjuvant radioiodine therapy in thyroid cancer patients.
        J Oncol. 2012; 2012: 1-11
        • Maxon H.R.
        • Thomas S.R.
        • Hertzberg V.S.
        • Kereiakes J.G.
        • Chen I.-W.
        • Sperling M.I.
        • et al.
        Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.
        N Engl J Med. 1983; 309: 937-941
        • Koral F.
        • Adler R.S.
        • Carey J.E.
        • et al.
        Iodine-131 treatment of thyroid cancer: Absorbed dose calculated from posttherapy scans.
        J Nucl Med. 1986; 1207–1211
        • O'Connell M.E.A.
        • Flower M.A.
        • Hinton P.J.
        • Harmer C.L.
        • McCready V.R.
        Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
        Radiother Oncol. 1993; 28: 16-26
        • Samuel A.M.
        • Rajashekharrao B.
        Radioiodine therapy for welldifferentiated thyroid cancer: A quantitative dosimetric evaluation for remnant thyroid ablation after surgery.
        J Nucl Med. 1994; 1944–1950
        • Lassmann M.
        • Luster H.
        • Hanscheid H.
        • et al.
        Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
        J Nucl Med. 2004; 45: 619-625
        • Flux G.D.
        • Haq M.
        • Chittenden S.J.
        • Buckley S.
        • Hindorf C.
        • Newbold K.
        • et al.
        A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.
        Eur J Nucl Med Mol Imaging. 2010; 37: 270-275
        • Mínguez P.
        • Flux G.
        • Genollá J.
        • Delgado A.
        • Rodeño E.
        • Sjögreen Gleisner K.
        Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131I-NaI treatments of differentiated thyroid cancer.
        Med Phys. 2016; 43: 5279-5287
        • Wierts R.
        • Brans B.
        • Havekes B.
        • Kemerink G.J.
        • Halders S.G.
        • Schaper N.N.
        • et al.
        Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
        J Nucl Med. 2016; 57: 1027-1032
        • Dewaraja Y.K.
        • Frey E.C.
        • Sgouros G.
        • Brill A.B.
        • Roberson P.
        • Zanzonico P.B.
        • et al.
        23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy.
        J Nucl Med. 2012; 53: 1310-1325
        • Mínguez P.
        • Rodeño E.
        • Genolla J.
        • et al.
        Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131 I-NaI respectively.
        Phys Med. 2019; 65: 143-149
        • Jönsson H.
        • Mattsson S.
        Single uptake measurement for absorbed dose planning for radioiodine treatment of hyperthyroidism.
        Cancer Biother Radiopharm. 2003; 18: 473-479
        • McDougall I.R.
        • Iagaru A.
        Thyroid Stunning: Fact or Fiction?.
        Semin Nucl Med. 2011; 41: 105-112
        • Heung H.W.D.
        • Humm J.L.
        • Larson S.M.
        Radioiodine Uptake in Thyroid Remnants During Therapy After Tracer Dosimetry.
        J Nucl Med. 2000; 41: 1082-1085
        • Sisson J.C.
        • Avram A.M.
        • Lawson S.A.
        • et al.
        The So-Called Stunning of Thyroid.
        J Nucl Med. 2006; 47: 1406-1412
      1. Sobin LH, GospodarowiczMK, Wittekind C. TNM classification of malignant tumors. Wiley-Blackwell. New York; 2009.

      2. International Atomic Energy Agency. Release of patients after radionuclide therapy. Safety Report Series No. 63, IAEA. Vienna; 2009.

      3. Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2016.

        • Jentzen W.
        • Freudenberg L.
        • Eising E.G.
        • Sonnenschein W.
        • Knust J.
        • Bockisch A.
        Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
        J Nucl Med. 2008; 49: 1017-1023
        • Gulec S.A.
        • Kuker R.A.
        • Goryawala M.
        • Fernandez C.
        • Perez R.
        • Khan-Ghany A.
        • et al.
        124I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis.
        Thyroid. 2016; 26: 441-448
      4. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.URL http://www.R-project.org/. 2020.

        • Hänscheid H.
        • Lassmann M.
        • Luster M.
        • et al.
        Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal.
        J Nucl Med. 2006; 47: 648-654
        • Brinks P.
        • Van Gils K.
        • Kranenborg E.
        • Lavalaye J.
        • Dickerscheid D.B.M.
        • Habraken J.B.A.
        Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study.
        Eur J Nucl Med Mol Imaging. 2017; 44: 935-940
        • Nordén M.M.
        • Larsson F.
        • Tedelind S.
        • Carlsson T.
        • Lundh C.
        • Forssell-Aronsson E.
        • et al.
        Down-regulation of the Sodium/Iodide Symporter Explains 131I-Induced Thyroid Stunning.
        Cancer Res. 2007; 67: 7512-7517
        • Walrand S.
        • Hesse M.
        • Jamar F.
        Statistical and radiobiological analysis of the so-called thyroid stunning.
        EJNMMI Research. 2015; 5: 67
        • Hilditch T.E.
        • Dempsey M.F.
        • Bolster A.A.
        • McMenemin R.M.
        • Reed N.S.
        Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
        Eur J Nucl Med. 2002; 29: 783-788
      5. Kobe C, Eschner W, Wild M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun 2010; 31:201-5.

        • Zhang R.
        • Zhang G.
        • Wang R.
        • Tan J.
        • He Y.
        • Meng Z.
        Prediction of thyroidal 131I effective half-life in patients with Graves' disease.
        Oncotarget. 2017; 8: 80934-80940